All posts tagged: Drug Development

CAC2 Webinar–What is a Pediatric Study Plan?

May 27, 2020
Webinars No comments yet
Our May CAC2 All-Member webinar focused on how pediatric cancer study plans are developed.  CAC2 Member Kelli Wright (CureSearch) introduced Dr. Brenda Weigel from University of Minnesota’s Masonic Cancer Center and Dr. Samuel Blackman of Day One Biopharmaceuticals as they addressed: What is a Pediatric Study Plan (PSP)? How is it created and by who? How does FDARA/RACE for Children impact PSP development? Where in the process are the opportunities to create better PSPs? Currently, regulatory agencies require that a pharmaceutical or biotechnology company submit a Pediatric Study Plan (PSP) to confirm the suitability of drug usage in the pediatric [...] Read more

Day One Biopharmaceuticals

May 21, 2020
Community News No comments yet

Day One Biopharmaceutical, a start-up biotech company founded with a focus on developing therapies for children with cancer through drug repurposing announced its debut in the market last week.  Its first agent, DAY101, licensed from Takeda Pharmaceuticals, is a targeted treatment for children with low grade glioma, a type of brain cancer. DAY101 is a Phase 2-ready RAF inhibitor that also shows strong potential for other pediatric and adult indications. The company is co-founded by Chief Medical Officer Dr. Sam Blackman (who offered our May webinar) and Acting CEO Julie Grant from Canaan Partners.   You can read more here.   Please look for a […]

Read more

CAC2 Webinar–Accelerating Drug Development for Children and Adolescents with Cancer

December 11, 2019
Webinars No comments yet
We were pleased to invite CAC2 members, associate members, student members, supporting organizations to our December CAC2 All-member webinar where Susan Weiner (Children's Cancer Cause) hosted Dr. Gilles Vassal, chair of ACCELERATE, an international nonprofit. Dr. Vassal discussed ACCELERATE and its fresh approach to addressing the complex challenges of developing innovative pediatric cancer therapies in the new regulatory environment. View the webinar below. Read more

CAC2 Webinar–Non-Profit Driven Pediatric Oncology Drug Development

May 25, 2016
Webinars No comments yet
In this All-Member webinar for May 2016, CAC2 welcomed Dr. Cesare Spadoni, Chairman and Co-Founder of Accelerating Paediatric Oncology Drug Development. Parents and non-profit entities can play a strong role in driving drug development and thus accelerate the availability of more innovative drugs for children with cancer. But to do, so they must adopt new operating models and collaborate more effectively with other stakeholders. https://youtu.be/GZVCYn-Rmek Read more

CAC2 Webinar–Dr. Jeffrey Skolnik, Basics of Pediatric Drug Development

November 17, 2014
Webinars No comments yet
On Wednesday, November 12, CAC2 had the privilege of hosting Jeffrey Skolnik, MD, US Medical Affairs Leader, Oncology, GlaxoSmithKline and Attending Physician, Children’s Hospital of Philadelphia. He presented our November All-Member webinar about the industry perspective in pediatric oncology drug development.   The views he expresses are his personal observations and not the official position of GSK or any other pharmaceutical company. https://youtu.be/Txrak33zR60 Read more
Archives

Enquire now

Give us a call or fill in the form below and we will contact you. We endeavor to answer all inquiries within 24 hours on business days.